The IL-36y is potential biomarker of psoriatic erythroderma


Cite item

Full Text

Abstract

Erythroderma is a rare and severe dermatological phenomenon caused by different diseases. The aim of the study was to analyze the value of IL-36γ immunohistology for the detection of psoriasis patients among those who suffer from erythroderma. The study was carried out on biopsy specimens from 56 erythroderma patients, who were treated in the department of dermatology of University Clinic of Bonn, Germany, and Skin and Venereology Clinic, the Leningrad region, between 2001 and 2013. Histological studies of the specimens were carried out for detection and classification of the underlying dermatosis, and Il36γ-immunohistology was studied. All the patients after histological analysis were divided into four groups. Group 1 included 17 patients with atopic erythroderma (eczema), group 2 consisted of 19 patients suffering from psoriasis, group 3 were 7 patients with T-cell lymphoma, and group 4 included 9 patients with drug reactions. Six patients were excluded from investigation as their histological pictures were nonspecific. Psoriasis patients showed a significantly higher expression of IL-36γ compared to other groups. The expression of IL-36γ was the most specific and sensitive marker, along with other histological criteria for the identification of psoriasis patients. Our results indicate that IL-36γ immunohistology is the most valuable marker for the detection of psoriasis in erythroderma patients. Psoriatic erythroderma can be rapidly diagnosed using this marker and specific therapy started.

About the authors

Denis V. Zaslavsky

St. Petersburg State Pediatric Medical University

Email: venerology@gmail.com
MD, PhD, DSc, prof. 194100, St. Petersburg, Russia

A. A Sydikov

St. Petersburg State Pediatric Medical University

кандидат мед. наук, врач-дерматолог 194100, St. Petersburg, Russia

I. N Chuprov

I.I. Mechnikov NorthWestern State Medical University

доктор мед. наук, доцент 191015, St. Petersburg, Russia

K. U Ibragimov

St. Petersburg State Pediatric Medical University

врач-патологоанатом 194100, St. Petersburg, Russia

R. A Nasyrov

St. Petersburg State Pediatric Medical University

доктор мед. наук, профессор 194100, St. Petersburg, Russia

Yu. S Egorova

St. Petersburg State Pediatric Medical University

кандидат мед. наук, доцент 194100, St. Petersburg, Russia

M. G Khvedelidze

St. Petersburg State Pediatric Medical University

ассистент, врач-дерматолог 194100, St. Petersburg, Russia

Jorg Wenzel

Rheinische Friedrich-Wilhelm-University

University Clinic of Bonn 53105 Bonn, Germany

References

  1. Vonderheid E.C., Bernengo M.G., Burg G., Duvic M., Heald P., Laroche L., et al.; ISCL. Update on erythrodermic cutaneous T-cell lymphoma: report of the international society for cutaneous lymphomas. J. Am. Acad. Dermatol. 2002; 46(1): 95-106.
  2. Sigurdsson V., Toonstra J., Hezemenas-Boer M., van Vloten W.A. Erythrodema: a clinical and follow-up study of 102 patients, with special emphasis on survival. J. Am. Acad. Dermatol. 1996; 35(1): 53-7.
  3. Dubrey S.W., Rosser G., Patel K., Whittaker S.J. Erythroderma is not all psoriasis: a case of Sezary syndrome. Br. J. Hosp. Med. (Lond). 2014; 75(1): 50-1.
  4. Ram-Wolff C., Martin-Garcia N., Bensussan A., Bagot M., Ortonne N. Histopathologic diagnosis of lymphomatous versus inflammatory erythroderma: a morphologic and phenotypic study on 47 skin biopsies. Am. J. Dermatopathol. 2010; 32(8): 755-63.
  5. Заславский Д.В., Чупров И.Н., Сыдиков А.А., Ибрагимов К.У., Волькенштейн П., Скрек С.В., Насыров Р.А. Роль маркера IL-36γ/IL-1F9 в развитии эритродермии у пациентов с псориазом. Казанский медицинский журнал. 2015; 1: 80-4.
  6. D’Erme A.M., Wilsmann-Theis D., Wagenpfeil J., Holzel M., Ferring-Schmitt S., Sternberg S., et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J. Invest. Dermatol. 2015; 135(4): 1025-32.
  7. Wenzel J., Worenkamper E., Freutel S., Henze S., Haller O., Bieber T., et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J. Pathol. 2005; 205(4): 435-42.
  8. Dinarello C., Arend W., Sims J., Smith D., Blumberg H., O’Neill L., et al. IL-1 family nomenclature. Nat. Immunol. 2010; 11(11): 973. doi: 10.1038/ni1110-973
  9. Vigne S., Palmer G., Lamacchia C., Martin P., Talabot-Ayer D., Rodriguez E., et al. IL-36R ligands are potent regulators of dendritic and T cells. Blood. 2011; 118(22): 5813-23.
  10. Marrakchi S., Guigue P., Renshaw B.R., Puel A., Pei X.Y., Fraitag S., et al. Interleukin-36-receptor antagonist deficiency and generalized pustular psoriasis. N. Engl. J. Med. 2011; 365(7): 620-8.
  11. Foster A.M., Baliwag J., Chen C.S., Guzman A.M., Stoll S.W., Gudjonsson J.E., et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin. J. Immunol. 2014; 192(12): 6053-61.
  12. Li N., Yamasaki K., Saito R., Fukushi-Takahashi S., Shimada-Omori R., Asano M., et al. Alarmin function of cathelicidin antimicrobial peptide LL37 through IL-36gamma induction in human epidermal keratinocytes. J. Immunol. 2014; 193(10): 5140-8.

Copyright (c) 2015 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies